News Sentiment

ANGO sentiment intelligence

AngioDynamics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 12.79 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

76/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-2.3% over one week, +5.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

AngioDynamics rises as Freedom Broker raises stock price target to $17

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 76/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 5.7% over four weeks
Fair value 44.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 24
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Stock Titan 7
Moomoo 4
Investing.com 4
Quiver Quantitative 3
TradingKey 3
Seeking Alpha 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 13
Regulatory and legal 9
Analyst action 6
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
Moomoo Direct company coverage

Press Release: AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

AngioDynamics (NASDAQ: ANGO) announced it will report its fiscal 2026 fourth quarter and full-year financial results on Tuesday, July 14, 2026, before the market opens. Management will host a conference call and webcast at 8:00 a.m. EDT to discuss the results and provide a busine

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 21:10
Source
Moomoo
Stock Titan Direct company coverage

AngioDynamics sets July 14 call for fiscal 2026 results

AngioDynamics announced it will report its fiscal year 2026 fourth quarter and full-year financial results on July 14, 2026, before market open. The company's management will host a conference call at 8:00 AM ET on the same day to discuss these results. The call details and webca

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 12:10
Source
Stock Titan
Zenopa Direct company coverage

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

AngioDynamics has received FDA Investigational Device Exemption (IDE) approval to begin the RELIEF study, evaluating its NanoKnife System for treating benign prostatic hyperplasia (BPH). This feasibility study will assess the irreversible electroporation (IRE) technology as a min

Tone
Positive 71/100
Event
Regulatory and legal
Published
27 Jun 2026 07:11
Source
Zenopa
TradingView Direct company coverage

AngioDynamics, Inc. Actuals & Estimates (NASDAQ:ANGO)

This article provides an in-depth financial overview of AngioDynamics, Inc. (NASDAQ:ANGO), including its stock performance, analyst estimates, historical prices, market capitalization, earnings, and revenue. It highlights ANGO's recent stock price increase, upcoming earnings repo

Tone
Positive 66/100
Event
Earnings
Published
25 Jun 2026 14:42
Source
TradingView
TradingView Direct company coverage

ANGO Forecast — Price Target — Prediction for 2027

This article provides a forecast for AngioDynamics, Inc. (ANGO) stock, including analyst price targets, past performance, and key financial metrics. It highlights that AngioDynamics is expected to release its next earnings report on July 21, 2026, and details previous earnings an

Tone
Positive 63/100
Event
Analyst action
Published
25 Jun 2026 13:10
Source
TradingView
AboutLawsuits.com Direct company coverage

AngioDynamics Port Catheter Lawsuit Claims Woman’s SmartPort Implants Caused Multiple Infections

A Georgia woman has filed a lawsuit against AngioDynamics and Navilyst Medical, alleging that two of their SmartPort implants caused her to suffer multiple infections, requiring repeated surgeries. The lawsuit claims that the port catheters were defectively designed and manufactu

Tone
Negative 13/100
Event
Regulatory and legal
Published
23 Jun 2026 14:09
Source
AboutLawsuits.com
TradingKey Direct company coverage

AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for AngioDynamics Inc (ANGO), noting its current valuation score of 7.26, which ranks 164th in the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio of -16.31, which is significantly below its recent

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 17:39
Source
TradingKey
TradingKey Direct company coverage

AngioDynamics Inc (ANGO) Institutional Confidence

AngioDynamics Inc (ANGO) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is currently 93.94%, a decrease of 11.97% quarter-over-quarter. Steven Cohen is the largest insti

Tone
Positive 71/100
Event
Market update
Published
19 Jun 2026 03:39
Source
TradingKey
Yahoo! Finance Canada Direct company coverage

ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study

AngioDynamics (ANGO) has received FDA IDE approval for its RELIEF study, which will evaluate the NanoKnife System's irreversible electroporation (IRE) technology for treating benign prostatic hyperplasia (BPH). This study expands the NanoKnife's clinical applications beyond oncol

Tone
Positive 67/100
Event
Regulatory and legal
Published
18 Jun 2026 09:52
Source
Yahoo! Finance Canada
grafa.com Direct company coverage

AngioDynamics receives FDA approval for RELIEF clinical study

AngioDynamics has received FDA approval for an Investigational Device Exemption to commence its RELIEF clinical study. This study will evaluate the NanoKnife System for treating lower urinary tract symptoms in men with benign prostatic hyperplasia, aiming to generate safety and e

Tone
Positive 77/100
Event
Regulatory and legal
Published
17 Jun 2026 12:55
Source
grafa.com
Investing.com Direct company coverage

AngioDynamics receives FDA approval for BPH treatment study

AngioDynamics (NASDAQ:ANGO) has received FDA approval for an Investigational Device Exemption application to commence its RELIEF study, investigating the use of its NanoKnife System for treating benign prostatic hyperplasia (BPH). The study will evaluate the system's irreversible

Tone
Positive 69/100
Event
Regulatory and legal
Published
17 Jun 2026 12:39
Source
Investing.com
Stock Titan Direct company coverage

AngioDynamics wins FDA okay to test NanoKnife in BPH patients

AngioDynamics (NASDAQ: ANGO) has received FDA approval for an Investigational Device Exemption (IDE) to initiate the RELIEF study. This feasibility study will evaluate the company's NanoKnife System, which uses irreversible electroporation (IRE) technology, as a minimally invasiv

Tone
Positive 67/100
Event
Regulatory and legal
Published
17 Jun 2026 12:39
Source
Stock Titan